Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents

European Journal of Medicinal Chemistry

Volumn 49, Issue , 2012, Pages 271-278

  Li, Siyuan ^a   Guo, Chunying ^a   Sun, Xianqiang ^a   Li, Yaozong ^a   Zhao, Hongli ^a   Zhan, Dongmei ^a   Lan, Minbo ^a,b   Tang, Yun ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bio probe; EGFR; Free radical; Inhibitor; Quinazoline

Indexed keywords

2,2,6,6 TETRAMETHYL 1 OXYL N [4 (3 BROMOPHENYLAMINO)QUINAZOLIN 6 YL]PIPERIDINE 4 CARBOXAMIDE; 2,2,6,6 TETRAMETHYL 1 OXYL N [4 (3 CHLORO 4 FLUOROPHENYLAMINO)QUINAZOLIN 6 YL]PIPERIDINE 4 CARBOXAMIDE; 2,2,6,6 TETRAMETHYL 1 OXYL N [4 (3 CHLOROPHENYLAMINO)QUINAZOLIN 6 YL]PIPERIDINE 4 CARBOXAMIDE; 4 (3 BROMOPHENYLAMINO) 6,7 DIMETHOXY N [(2,32,6,6 TETRAMETHYL 1 OXYL)PIPERIDIN 4 YL]QUINOLINE 3 CARBOXAMIDE; 4 (3 CHLORO 4 FLUOROPHENYLAMINO) 6,7 DIMETHOXY N [(2,32,6,6 TETRAMETHYL 1 OXYL)PIPERIDIN 4 YL]QUINOLINE 3 CARBOXAMIDE; 4 (3 CHLOROPHENYLAMINO) 6,7 DIMETHOXY N [(2,32,6,6 TETRAMETHYL 1 OXYL)PIPERIDIN 4 YL]QUINOLINE 3 CARBOXAMIDE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; LAPATINIB; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG INHIBITION; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOLECULAR DOCKING;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; MODELS, MOLECULAR; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPIN LABELS;

EID: 84862814725     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.01.021     Document Type: Article

References (34)

1. A. Antonello, A. Tarozzi, F. Morroni, A. Cavalli, M. Rosini, P. Hrelia, M.L. Bolognesi, and C. Melchiorre Multitarget-directed drug design strategy: a novel molecule designed to block epidermal growth factor receptor (EGFR) and to exert proapoptotic effects J. Med. Chem. 49 2006 6642 6645 (Pubitemid 44749729)
2. Z. Rachid, F. Brahimi, Q. Qiu, C. Williams, J.M. Hartley, J.A. Hartley, and B.J. Jean-Claude Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship J. Med. Chem. 50 2007 2605 2608 (Pubitemid 46896067)
3. S. Bishayee Role of conformational alteration in the epidermal growth factor receptor (EGFR) function Biochem. Pharmacol. 60 2000 1217 1223
4. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, J.-H. Kim, K. Saito, A. Sakamoto, M. Inoue, M. Shirouzu, and S. Yokoyama Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110 2002 775 787 (Pubitemid 35291060)
5. T. Holbro, G. Civenni, and N.E. Hynes The ErbB receptors and their role in cancer progression Exp. Cell Res. 284 2003 99 110 (Pubitemid 36331969)
6. N. Hynes, K. Horsch, M. Olayioye, and A. Badache The ErbB receptor tyrosine family as signal integrators Endocr. Relat. Cancer 8 2001 151 159 (Pubitemid 32947637)
7. C. Kuan, C. Wikstrand, and D. Bigner EGF mutant receptor vIII as a molecular target in cancer therapy Endocr. Relat. Cancer 8 2001 83 96 (Pubitemid 32641351)
8. Y. Umekita, Y. Ohi, Y. Sagara, and H. Yoshida Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients Int. J. Cancer 89 2000 484 487
9. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr. , M.V. Di Maria, R. Veve, R.M. Bremnes, A.E. Baron, C. Zeng, and W.A. Franklin Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis J. Clin. Oncol. 21 2003 3798 3807 (Pubitemid 46606235)
10. B. Biersack, M. Zoldakova, K. Effenberger, and R. Schobert (Arene)Ru(II) complexes of epidermal growth factor receptor inhibiting tyrphostins with enhanced selectivity and cytotoxicity in cancer cells Eur. J. Med. Chem. 45 2010 1972 1975
11. A. Bourkoula, M. Paravatou-Petsotas, A. Papadopoulos, I. Santos, H.-J. Pietzsch, E. Livaniou, M. Pelecanou, M. Papadopoulos, and I. Pirmettis Synthesis and characterization of rhenium and technetium-99m tricarbonyl complexes bearing the 4-[3-bromophenyl]quinazoline moiety as a biomarker for EGFR-TK imaging Eur. J. Med. Chem. 44 2009 4021 4027
12. T. Fozing, C. Scheuer, and S. Samnick Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer Eur. J. Med. Chem. 45 2010 3780 3786
13. J. Domarkas, F. Dudouit, C. Williams, Q. Qiyu, R. Banerjee, F. Brahimi, and B.J. Jean-Claude The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR) J. Med. Chem. 49 2006 3544 3552 (Pubitemid 43902460)
14. M.B. Gariboldi, S. Lucchi, C. Caserini, R. Supino, C. Oliva, and E. Monti Antiproliferative effect of the piperidine nitroxide tempol on neoplastic and nonneoplastic mammalian cell lines Free Radic. Biol. Med. 24 1998 913 923 (Pubitemid 28186232)
15. M.B. Gariboldi, R. Ravizza, C. Petterino, M. Castagnaro, G. Finocchiaro, and E. Monti Study of in vitro and in vivo effects of the piperidine nitroxide Tempol-a potential new therapeutic agent for gliomas Eur. J. Cancer 39 2003 829 837 (Pubitemid 36316001)
16. M.B. Gariboldi, V. Rimoldi, R. Supino, E. Favini, and E. Monti The nitroxide tempol induces oxidative stress, p21WAF1/CIP1, and cell death in HL60 cells Free Radic. Biol. Med. 29 2000 633 641
17. E. Monti, R. Supino, M. Colleoni, B. Costa, R. Ravizza, and M.B. Gariboldi Nitroxide TEMPOL impairs mitochondrial function and induces apoptosis in HL60 cells J. Cell. Biochem. 82 2001 271 276 (Pubitemid 32606290)
18. F. Hyodo, K.-i. Matsumoto, A. Matsumoto, J.B. Mitchell, and M.C. Krishna Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents Cancer Res. 66 2006 9921 9928 (Pubitemid 44672044)
19. P. Kuppusamy, M. Afeworki, R.A. Shankar, D. Coffin, M.C. Krishna, S.M. Hahn, J.B. Mitchell, and J.L. Zweier In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model Cancer Res. 58 1998 1562 1568 (Pubitemid 28193625)
20. K.-i. Matsumoto, F. Hyodo, A. Matsumoto, A.P. Koretsky, A.L. Sowers, J.B. Mitchell, and M.C. Krishna High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents Clin. Cancer Res. 12 2006 2455 2462
21. H.-R. Tsou, N. Mamuya, B.D. Johnson, M.F. Reich, B.C. Gruber, F. Ye, R. Nilakantan, R. Shen, C. Discafani, R. DeBlanc, R. Davis, F.E. Koehn, L.M. Greenberger, Y.-F. Wang, and A. Wissner 6-Substituted-4-(3-bromophenylamino) quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity J. Med. Chem. 44 2001 2719 2734 (Pubitemid 32879714)
22. A. Wissner, D.M. Berger, D.H. Boschelli, M.B. Floyd, L.M. Greenberger, B.C. Gruber, B.D. Johnson, N. Mamuya, R. Nilakantan, M.F. Reich, R. Shen, H.-R. Tsou, E. Upeslacis, Y.F. Wang, B. Wu, F. Ye, and N. Zhang 4-Anilino-6,7- dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7- dialkoxyquinazoline inhibitors J. Med. Chem. 43 2000 3244 3256
23. S.R. Klutchko, H. Zhou, R.T. Winters, T.P. Tran, A.J. Bridges, I.W. Althaus, D.M. Amato, W.L. Elliott, P.A. Ellis, and M.A. Meade Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido [3, 4-d] pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors J. Med. Chem. 49 2006 1475 1485 (Pubitemid 43271900)
24. C. Fernandes, C. Oliveira, L. Gano, A. Bourkoula, I. Pirmettis, and I. Santos Radioiodination of new EGFR inhibitors as potential SPECT agents for molecular imaging of breast cancer Bioorg. Med. Chem. 15 2007 3974 3980 (Pubitemid 46695828)
25. 2-induced damage and their protection by nitroxides Biochim. Biophys. Acta (BBA). Gen. Subjects 1525 2001 70 76 (Pubitemid 32149979)
26. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, S.H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K.J. Alligood, D.W. Rusnak, T.M. Gilmer, and L. Shewchuk A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) Cancer Res. 64 2004 6652 6659
27. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272 (Pubitemid 35417619)
28. C.-H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, M. Meyerson, and M.J. Eck Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227 (Pubitemid 46349842)
29. J.F.W. Keana Newer aspects of the synthesis and chemistry of nitroxide spin labels Chem. Rev. 78 1978 37 64
30. C.E. Müller, R. Hrdina, R.C. Wende, and P.R. Schreiner A multicatalyst system for the one-pot desymmetrization/oxidation of meso-1,2-alkane diols Chem. Eur. J. 17 2011 6309 6314
31. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63 (Pubitemid 14203433)
32. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The protein data Bank Nucleic Acids Res. 28 2000 235 242 (Pubitemid 30047768)
33. Maestro, Schrödinger, LLC, New York, NY, 2008.
34. Ligprep, Schrödinger, LLC, New York, NY, 2008.